StockWatch
·

HIKAL LTD. Q2 FY27 Results

HIKALQ2 FY27 Results
Filing
Result:Weak· Market: Down#Margin expansion#Base effect

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue434.207.8%36.3%
Total Income435.907.7%36.0%
Expenditure444.405.0%21.0%
PBT-8.5014.1%81.9%
Net Profit-6.1017.6%82.5%
OPM10.34%1.06pp8.08pp
NPM-1.40%0.43pp9.49pp
EPS-0.49181.7%
View full financials

Pharma's core metric (adjusted net profit) remains a loss for a fifth straight quarter despite 36.3% revenue growth and OPM expansion to 10.3%, so the hard rule caps it below good even though the loss is narrowing sharply off a depressed, USFDA-warning-letter-hit base.

HIKAL LTD · Q2 FY-2027 · THE VERDICT

36% growth, ₹6 crore loss: Hikal's profitability promise stalls

Revenue surged to ₹434 crore, but the company posted a ₹6.1 crore loss—and profitability actually deteriorated from H1. Management reiterated mid-teens growth guidance while acknowledging 100%+ raw material inflation, ongoing FDA remediation costs, and a crop protection segment that turned loss-making. The tension between headline growth and operating leverage collapse defines this quarter.

05 Nov 2026 · 6 min read
Q2 Revenue

₹434 Cr

+36% YoY, +7.8% QoQ

Q2 PAT

-₹6.1 Cr

Loss; H1 PAT -₹14 Cr

OPM

10.3%

Flat vs H1, compressed vs prior year

Pharma EBIT margin

4.6%

vs 13.7% prior year: 900bps drop

The core tension: scale without leverage

Revenue accelerated 36% year-over-year to ₹434 crore, yet the company reported a ₹6.1 crore loss. This isn't a one-time item reconciliation—it's a deterioration in the cash profit frame. H1 PAT sits at -₹14 crore negative, a swing from prior year profitability. Operating margin at 10.3% is being crushed by cost of goods sold that's up faster than pricing power. The earnings call made clear why: raw material costs and solvents inflated over 100%, the company is still deep in FDA remediation expenses at ₹20 crore annually, and the crop protection segment—which carries 36% of revenue—turned sharply loss-making (Q2 EBIT -₹2 crore, H1 EBIT -₹8 crore).

₹ Crore
-116.12235.63587.37939.12837H1 Revenue82H1 EBITDA-14H1 PAT
Six-month profit trajectory: despite ₹837 Cr revenue and ₹82 Cr EBITDA, the company is PAT-negative. Operating leverage has reversed.

Management's claims vs. what holds up

Guidance and on-call assertions tested against Q2 results

Q2 revenue ₹434 Cr with EBITDA ₹45 Cr, OPM 10.3%

Supported

Delivered: ₹434.2 Cr revenue, OPM 10.3%—numbers match

Substantial improvement in profitability expected; margins will recover

Contradicted

Q2 PAT -₹6.1 Cr; H1 PAT -₹14 Cr. Company posted losses despite 36% revenue growth

Pharma mid-teens H2 growth; reiterated full-year mid-teens guidance

Overstated

Pharma Q2 ₹278 Cr EBIT margin 4.6% vs ~13.7% prior year (900bps drop on near-flat volume). H2 contingent on FDA clearance by FY27 end

CDMO contract signed; commercial launch FY27 end with high-margin contribution

Partial

Contract secured but 2–2.5 year gestation timeline; no Q2 revenue yet. Launch 'FY27 end' is aspirational; actual ramp multi-quarter

Crop Protection navigating raw material inflation; customer pass-through underway

Overstated

Q2 EBIT -₹2 Cr (margin -1.5%), H1 EBIT -₹8 Cr (margin -2.5%). Segment loss-making; no pass-through evidence yet

What changed on this call

Bull-bear ledger

  • Revenue accelerated 36% YoY despite sector headwinds (crop, raw materials)

  • CDMO contract is a genuine new revenue stream with high-margin profile

  • Regulatory reach expanding (ANVISA Brazil, PMDA Japan, Swissmedic Europe)

  • Animal Health ₹400 Cr ambition by FY30 is multi-year growth lever

  • PAT negative ₹6.1 Cr in Q2 despite ₹434 Cr revenue—operating leverage is broken

  • Pharma EBIT margin collapsed 900bps YoY; raw material pass-through is assumed not assured

  • Crop Protection segment is now loss-making; Chinese dumping and weak demand structural

  • FDA remediation cost ₹20 Cr/yr ongoing through FY27; blocks profitability recovery

  • Guidance of 'substantial profitability improvement' reiterated but Q2 contradicts it

Risks ranked by how much they should concern a holder

Three high-severity risks dominate the outlook

FDA Bangalore reinspection delayed; blocks profitability recovery

High

Expected by FY27 end (March 2027) but no confirmed timeline. Each quarter of delay pushes margin recovery and new pharma DMF approvals into FY28. Profitability guidance credibility depends on this.

Raw material pass-through not yet realized; margin risk escalates

High

Management assumes majority of 100%+ input cost increases will flow through to customers 'over next quarters,' but no evidence in Q2 pricing data. If pass-through fails or lags, margins stay compressed indefinitely.

Crop Protection segment structural, not cyclical; 36% of revenue at risk

High

Q2 and H1 both deeply negative (EBIT -₹2 Cr and -₹8 Cr respectively). Chinese competition and inventory overhang cited as 'structural.' If segment doesn't recover, it's a permanent ₹300+ Cr revenue base dragging on consolidated margins.

Profitability guidance reiterated despite Q2 loss contradicting it

Medium

Management claims 'substantial improvement' but delivered loss in Q2. Credibility grade 'C' on the call. If H2 doesn't deliver materially better PAT, guidance loses all weight.

Geopolitical and weather volatility (management's cited wildcard)

Medium

Management explicitly cited 'geopolitical situation' and 'weather impacts' as wildcards that could reduce H2 EBITDA margin guidance by 100bps. Uncontrollable tail risk.

How the street is positioning

The price action tells a different story than the fundamentals. The stock is at ₹222.63, up 52% off its 52-week low (₹146.25) but still -70% from its all-time high (₹742). Short-term momentum is bullish: the stock trades above its 20-day, 50-day, and 200-day moving averages (₹211.28, ₹216.52, and ₹204.10 respectively), and volume is increasing. RSI at 56.6 signals neutral momentum—not oversold, not overbought. This rally is likely a bounce off depressed valuations, not a fundamental revaluation.

But ownership flows tell the real story: FII shareholding has collapsed from 5.69% a year ago to 0.99% as of Q1 FY27—a systematic sell-off by a full 4.7 percentage points. DII ownership is stable at ~7%, and promoters hold steady at 68.85%. The foreign exodus suggests institutions have seen enough of the margin compression and profitability deterioration to exit at higher valuations. Bulk deals in early September (₹244–₹246 range) show balanced buying and selling, with no suspicious insider-linked selling. The September activity pre-dates the earnings miss, so it's not a tell.

The disconnect is stark: price action is rewarding the 36% revenue bump, but fundamentals show operating leverage has snapped. FII has already voted with its feet. A bounce off the 52-week low is natural, but the all-time high of ₹742 sits 70% above current levels—a reminder that Hikal was once valued for double-digit organic profit growth, not losses at scale.

What to watch next
  • 1 · FDA Bangalore reinspection clearance timeline

    The single most important unlock. Any indication that the reinspection will slip past March 2027 (FY27 end) is a 'downgrade to reduce' signal. Conversely, clearance by calendar Q4 2026 (before March) would validate H2 margin recovery.

  • 2 · Raw material pass-through evidence in Q3 pricing

    Look for revenue per unit growth in Q3 (October–December 2026) without corresponding volume gains. If pricing is flat or declining despite claimed pass-through, the margin recovery thesis is broken.

  • 3 · Crop Protection EBIT turn positive

    This is the non-negotiable proof point. If Crop Protection remains loss-making in Q3, it signals the segment is indeed structural and not a trough. If EBIT turns positive, the inventory-depletion thesis holds.

Hikal posted headline revenue growth that masks a profitability collapse. The company is profitable on paper only because EBITDA is positive; cash profit (PAT) is negative, FDA remediation costs are structural, and the crop protection business is a drag. Management reiterated guidance but Q2 results say the company missed on both revenue growth sustainability and profitability improvement.

Rating: Hold. The stock has bounced 52% off its low and trades above its moving averages, but FII outflows and the -70% drawdown from the all-time high are warnings. Until management demonstrates FDA clearance, raw material pass-through, and crop recovery in Q3 and Q4, this is a prove-it story, not a momentum play. The number to track from here: Q3 pharma EBIT margin—if it recovers toward 10%+ (away from Q2's 4.6%), the thesis holds. If it stays compressed, margins may not recover even if volume grows.

Informational and educational content only. Not investment advice.